PMID- 29050347
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 41
DP  - 2017 Sep 19
TI  - Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.
PG  - 71117-71127
LID - 10.18632/oncotarget.16759 [doi]
AB  - We conducted a meta-analysis to assess the efficacy and safety of dose-dense 
      chemotherapy in the treatment of patients with urothelial carcinoma. A systematic 
      search was conducted in PubMed, Medline, Embase, Web of Science and Cochrane 
      Collaboration's Central register of controlled trials (CENTRAL) for relevant 
      articles. Data was obtained from 10 trials with a total of 1093 patients. The 
      pooled pathologic complete response (pCR) was 27.8% in the ten studies with a 
      full cohort of 684 patients who received dose-dense methotrexate, vinblastine, 
      adriamycin and cisplatin (dd-MVAC). In the controlled trials, although the 
      difference was not significant, the pCR rate in the dd-MVAC group has a trend of 
      increase (odds ratio (OR) 1.52; 95% confidence interval (CI) 0.78-2.98, P = 0.22) 
      compared with classic MVAC group. A significant improvement of overall survival 
      (OS) (hazard ratio (HR) 0.77, 95% CI 0.61-0.97, p = 0.03) was also observed. 
      Hematologic toxicities were the most frequent grade >/= 3 toxicities including 
      neutropenia/febrile neutropenia (17.5%), anemia (9.4%) and thrombocytopenia 
      (6.1%). Compared with the classic MVAC group, dd-MVAC was associated with 
      significantly decreased risks of all-grade adverse events (AEs) such as anemia 
      (OR 0.457, 95% CI 0.249-0.840, p = 0.012), febrile neutropenia (OR 0.398 95% CI 
      0.233-0.681, p = 0.001), and neutropenia (OR 0.373, 95% CI 0.201-0.691, p = 
      0.002). In conclusion, dose-dense chemotherapy was effective and tolerable in 
      patients with urothelial carcinoma, which could be considered as a reasonable 
      therapeutic option.
FAU - Zhu, Chenjing
AU  - Zhu C
AD  - Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
FAU - Liu, Jiaming
AU  - Liu J
AD  - Department of Urology, Institute of Urology, Laboratory of Reconstructive 
      Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Li, Qingfang
AU  - Li Q
AD  - Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
FAU - Lian, Qisi
AU  - Lian Q
AD  - West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China.
FAU - Xu, Jing
AU  - Xu J
AD  - West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Ma, Xuelei
AU  - Ma X
AD  - Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan 
      University, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
DEP - 20170331
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5642622
OTO - NOTNLM
OT  - dose-dense
OT  - meta-analysis
OT  - urothelial carcinoma
COIS- CONFLICTS OF INTEREST None.
EDAT- 2017/10/21 06:00
MHDA- 2017/10/21 06:01
PMCR- 2017/09/19
CRDT- 2017/10/21 06:00
PHST- 2016/08/08 00:00 [received]
PHST- 2017/03/22 00:00 [accepted]
PHST- 2017/10/21 06:00 [entrez]
PHST- 2017/10/21 06:00 [pubmed]
PHST- 2017/10/21 06:01 [medline]
PHST- 2017/09/19 00:00 [pmc-release]
AID - 16759 [pii]
AID - 10.18632/oncotarget.16759 [doi]
PST - epublish
SO  - Oncotarget. 2017 Mar 31;8(41):71117-71127. doi: 10.18632/oncotarget.16759. 
      eCollection 2017 Sep 19.